Opus Genetics (NASDAQ:IRD) Earns “Buy” Rating from HC Wainwright

Opus Genetics (NASDAQ:IRD)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $8.00 price target on the stock.

Opus Genetics Trading Down 2.8 %

Shares of Opus Genetics stock opened at $0.98 on Tuesday. Opus Genetics has a 12-month low of $0.81 and a 12-month high of $1.56. The business’s 50 day moving average is $1.08. The company has a market cap of $31.46 million, a PE ratio of -0.90 and a beta of 0.28.

Opus Genetics (NASDAQ:IRD) last posted its quarterly earnings results on Monday, March 31st. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.93). Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%. The firm had revenue of $3.40 million for the quarter, compared to the consensus estimate of $11.10 million. Analysts forecast that Opus Genetics will post -1.22 earnings per share for the current fiscal year.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.